Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30894837 | 1.00 | KMT2A (0.55) | KMT2AOPRK1APEX1HSD17B10ACHE | |
| SCHEMBL5873486 | 0.84 | KDM4E (0.54) | KMT2AOPRK1ACHEMEN1ALDH1A1 | |
| SCHEMBL3763346 | 0.84 | LMNA (0.58) | KMT2AOPRK1APEX1HSD17B10ACHE | |
| SCHEMBL17478740 | 0.84 | KMT2A (0.52) | KMT2AOPRK1APEX1HSD17B10ACHE | |
| SCHEMBL5873698 | 0.81 | KMT2A (0.50) | KMT2AOPRK1APEX1ACHEMEN1 | |
| SCHEMBL6605853 | 0.81 | KMT2A (0.50) | KMT2AOPRK1APEX1HSD17B10ACHE | |
| SCHEMBL11822266 | 0.81 | NPBWR1 (0.56) | KMT2AOPRK1APEX1ACHEMEN1 | |
| SCHEMBL6603601 | 0.80 | KMT2A (0.49) | KMT2AOPRK1APEX1HSD17B10ACHE | |
| SCHEMBL6534272 | 0.80 | ELANE (0.64) | KMT2AOPRK1MEN1ALDH1A1NPBWR1 | |
| SCHEMBL30894828 | 0.80 | ALDH1A1 (0.53) | KMT2AOPRK1APEX1HSD17B10ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125372-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF | ASTELLAS ENG SMALL MOLECULES US INCORPORATED (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4608825-A1 | FUSED AZINES AS DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024091489-A1 | FUSED AZINES AS DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF | MITOBRIDGE, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091489-A1 | FUSED AZINES AS DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF | MITOBRIDGE, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-103717589-B | For treating or prevent the compound of respiratory syncytial virus disease | 弗·哈夫曼-拉罗切有限公司 | 2016-08-17 | — | — | CN | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| EP-1819342-A4 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2007-12-20 | — | — | US | disclosed |
| EP-1819342-A1 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006060390-A1 | QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20050165006-A1 | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same | HYUNDAI PHARM. IND. CO., LTD. (KR) | 2005-07-28 | — | — | US | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003082286-A1 | QUINOLINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHEMON INC. (KR) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165006-A1 | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same | SLC18A2, SLC6A4, SLC6A2 | KMT2A 3642/4885OPRK1 225/4885APEX1 4351/4885 |
| US-20070293492-A1 | Quinoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | KMT2A 1330/4885OPRK1 17/4885APEX1 3150/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | KMT2A 2880/4885OPRK1 4574/4885APEX1 4823/4885 |
| US-20260125372-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS AND USES THEREOF | DNM1L, DNM1, DNM2 | KMT2A 4170/4885OPRK1 943/4885APEX1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.